Population Covered By The Guidance
This pathway provides guidance on the investigation of adult patients with hypertension who need investigation for causes of secondary hypertension.
Lead Researcher: Sian Chin
Experts & Contributors: Aron Chakera, Ravinder Dhillon
Editorial Panel: Core membership
Link to Editorial Panel
Date reviewed: July 2018
Date Published: March 2019
- Secondary hypertension is uncommon and blanket screening for secondary hypertension is not routinely recommended
- If clinic blood pressure is ≥140/90mmHg, or hypertension is suspected, ambulatory and/or home monitoring should be offered to confirm the blood pressure level
- In cases of apparent resistant hypertension, it is important to specifically ask about medication compliance
- The initial assessment of patients with a new diagnosis of hypertension should include a thorough history and examination to elicit features that may suggest specific causes of secondary hypertension, as well as evidence of target organ damage. Basic screening tests include: urine dipstick, urinary albumin/creatinine ratio, fasting blood glucose, fasting lipid profile, serum urea, electrolytes, creatinine with eGFR, haemoglobin, fundoscopy and ECG (to assess for left ventricular hypertrophy)
- There are many causes of secondary hypertension and investigations should be targeted depending on the differential diagnosis
- Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-54. (Review article).View the reference
- Ng FL, Lobo MD. Investigation and management of adult hypertension. Heart. 2018. (Review article).View the reference
- National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults - 2016. Melbourne: National Heart Foundation of Australia; 2016. (Guideline). View the reference
- Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269-324. (Guideline). View the reference
- Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5):557-76. (Guideline). View the reference
- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. (Guideline). View the reference
Pathway User Guide
Yellow Boxes Denotes extra information. Some contain single or multiple white sub-boxes, click a white box to reveal detailed information in a pop-up.
White Boxes: Denotes standard pathway steps. (If inside a yellow box, they open a specific pop-up).
Zoom & Pan Controls: Use + / − or the slider to zoom. Reset returns to default. Tick Panning to drag the diagram when zoomed.
Blue “View Full Screen” Button: Opens the whole diagram in a large, full-screen pop-up window. Use Close to exit.
The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box.
| SYMBOL | RRL | EFFECTIVE DOSE RANGE |
|---|---|---|
| None | 0 | |
| Minimal | < 1 millisieverts | |
| Low | 1-5 mSv | |
| Medium | 5-10 mSv | |
| High | >10 mSv |
Disclaimer
Status Of Recommendations Each pathway is designed to assist clinicians in situations when faced with a large array of possible diagnostic tests and examinations. However, it is recognised that diagnostic practice may differ from a particular pathway depending on local availability of equipment and expertise, as well as the experience of individual clinicians. Therefore each pathway is neither a rigid set of rules, nor a substitute for clinical assessment, and individual patient circumstances should always be considered.
Spotted an error or outdated info? Click to tell us.
Screening for Secondary Hypertension
Screening for Secondary Hypertension
Secondary hypertension is rare and blanket screening is not recommended but certain features may prompt further investigation
- Only 5-10% of patients with hypertension have secondary hypertension
- Blanket screening for secondary hypertension is not routinely recommended
- If clinic blood pressure is ≥140/90mmHg, or hypertension is suspected, ambulatory and/or home monitoring should be offered to confirm the blood pressure level
- The initial assessment of patients with a new diagnosis of hypertension should include a thorough history and examination to elicit features that may suggest specific causes of secondary hypertension, as well as evidence of target organ damage. Basic screening tests include: urine dipstick, urinary albumin/creatinine ratio, fasting blood glucose, fasting lipid profile, serum urea, electrolytes, creatinine with eGFR, haemoglobin, fundoscopy and ECG (to assess for left ventricular hypertrophy)
- In cases of apparent resistant hypertension, it is important to specifically ask about medication compliance
- Screening for specific form(s) of secondary hypertension is recommended in certain circumstances:
Characteristics Suggestive of Secondary Hypertension
- Early onset 1,4,5
- Resistant hypertension – (>140/90mmHg despite three antihypertensive agents including a diuretic)
- Severe hypertension >180/110mmHg or hypertensive emergencies
- Exacerbation of previously controlled hypertension
- Clinical features specific to certain secondary causes – including biochemical abnormalities (such as excessive hyperkalaemia ), or renal dysfunction
There are many causes of secondary hypertension and investigations should be targeted depending on the differential diagnosis
- Causes of secondary hypertension include:
- Renal parenchymal disease
- Renovascular disease, including renal artery stenosis due to fibromuscular dysplasia
- Primary hyperaldosteronism
- Obstructive sleep apnoea (although there is mixed evidence on the benefit of treatment)
- Drug or alcohol induced
- Rarer causes:
- Phaeochromocytoma
- Cushing’s syndrome
- Hypo/hyperthyroidism
- Aortic coarctation
- Primary hyperparathyroidism
- Congenital adrenal hyperplasia
- Other mineralocorticoid excess syndromes
- Acromegaly
Renovascular Hypertension
Renovascular Hypertension
May be suspected in resistant hypertension. Can be caused by atherosclerotic disease, or by fibromuscular dysplasia especially in younger female patients without other risk factors
Phaeochromocytoma
Phaeochromocytoma
May have resistant, labile or paroxysmal hypertension including hypertensive crises. May have other symptoms of catecholamine excess. Consider in patients with predisposition to hereditary causes
Hyperaldosteronism
Hyperaldosteronism
Suspect if unexplained hypokalaemia is present
Cushing’s Syndrome
Cushing’s Syndrome
Suspect if other clinical features of Cushing’s Syndrome are present such as weight gain, hyperglycaemia, “moon” face and central obesity
Hyperthyroidism
Hyperthyroidism
Can be suspected if other clinical features are consistent with hyperthyroidism such as palpitations, weight loss, diarrhea, tremor or ophthalmopathy
